Table 2.

Table showing relative agonist efficacies and potencies of the ligands for transactivation via the GR on GRE and GILZ gene^*

	Transactivation
	COS-1		PBMC
	GRE		GILZ
Ligand	MAX (%) ± SEM	EC50 (M) ± SEM	MAX (%) ± SEM	EC50 (M) ± SEM
DEX	100 ± 2.17a	1.07 ± 0.55×10−9a	100 ± 4.87a	1.91 ± 2.51×10−8a
MPA	84.36 ± 3.99b	4.17 ± 1.63×10−8a	98.47 ± 7.09a	2.5 ± 0.66×10−7a
NET	ND	ND	6.50 ± 2.34b	5.12 ± 9.91×10−8#a
LNG	ND	ND	ND	ND
ETG	45.88 ± 4.97c	3.19 ± 1.21×10−8a	15.85 ± 2.29b	2.04 ± 3.19×10−7a
NES	55.81 ± 4.85c	1.85 ± 0.77×10−8a	40.70 ± 4.40c	1.47 ± 1.01×10−7a

^*Data shown in Fig. 2A and 2B, were analyzed to obtain the MAX (%) ± SEM and EC₅₀ (M) ± SEM values for each ligand for the GR.

^a,b,c,dStatistical significance between treatment groups was determined using one-way ANOVAs with Tukey post-test.

^#The EC₅₀ values for NET should be interpreted with caution as very weak agonist activity was observed.

ND-not determined.